TY - JOUR
T1 - Practical study of sublingual immunotherapy in patients with japanese cedar pollinosis using a questionnaire comparison among the first season, second season and third season
AU - Ohta, Nobuo
AU - Yuta, Atsushi
AU - Ogawa, Yukiko
AU - Shoji, Fumi
AU - Awataguchi, Toshiichi
AU - Suzuki, Naohiro
AU - Chiba, Toshihiko
AU - Chin, Shiketsu
AU - Kusakari, Chikashi
AU - Takeda, Kousei
AU - Kanbayashi, Junichi
AU - Shiga, Nobuyuki
AU - Otake, Yusuke
AU - Suzuki, Yusuke
AU - Shibahara, Yoshihiro
AU - Nakabayashi, Seiichiro
AU - Inamura, Naoki
AU - Osafune, Hiroshi
AU - Wada, Kota
AU - Kakehata, Seiji
AU - Katori, Yukio
AU - Okamoto, Yoshitaka
N1 - Publisher Copyright:
© 2018 Oto-Rhino-Laryngological Society of Japan Inc. All rights reserved.
PY - 2019
Y1 - 2019
N2 - Sublingual immunotherapy has been applied to patients with Japanese cedar pollinosis since 2014. However, no studies have been carried out to determine the efficacy of this treatment over the long term. Patients with Japanese cedar pollinosis who received this treatment from 2014 to 2017 were enrolled in this study. The clinical usage level, satisfaction level, and adverse effects of this treatment were investigated using a questionnaire among three groups patients treated from 2014 to 2017. The clinical usage level was more than 90% in all three groups, which was within acceptable limits. The subjective symptoms improved and the patients were satisfied with this treatment in all three groups. Of 356 patients, 32(9.2%)developed adverse effects with those involving the oral cavity and throat being the most common. Most adverse effects developing during the maintenance phase occurred within the first few weeks. All adverse effects in the present study were minor, and none necessitated treatment discontinuation. The incidence of side effects was higher in the first season than in the second season and third season(26.5%, 0% and 2.9%, respectively). These results led us to conclude that sublingual immunotherapy is an effective therapy for Japanese cedar pollinosis. However, clinicians must bear in mind that the appropriate management of adverse effects is mandatory for safety.
AB - Sublingual immunotherapy has been applied to patients with Japanese cedar pollinosis since 2014. However, no studies have been carried out to determine the efficacy of this treatment over the long term. Patients with Japanese cedar pollinosis who received this treatment from 2014 to 2017 were enrolled in this study. The clinical usage level, satisfaction level, and adverse effects of this treatment were investigated using a questionnaire among three groups patients treated from 2014 to 2017. The clinical usage level was more than 90% in all three groups, which was within acceptable limits. The subjective symptoms improved and the patients were satisfied with this treatment in all three groups. Of 356 patients, 32(9.2%)developed adverse effects with those involving the oral cavity and throat being the most common. Most adverse effects developing during the maintenance phase occurred within the first few weeks. All adverse effects in the present study were minor, and none necessitated treatment discontinuation. The incidence of side effects was higher in the first season than in the second season and third season(26.5%, 0% and 2.9%, respectively). These results led us to conclude that sublingual immunotherapy is an effective therapy for Japanese cedar pollinosis. However, clinicians must bear in mind that the appropriate management of adverse effects is mandatory for safety.
KW - Japanese cedar pollinosis
KW - Questionare
KW - Sublingual immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85063040855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063040855&partnerID=8YFLogxK
U2 - 10.3950/jibiinkoka.122.35
DO - 10.3950/jibiinkoka.122.35
M3 - Article
AN - SCOPUS:85063040855
SN - 0030-6622
VL - 122
SP - 35
EP - 44
JO - Journal of Otolaryngology of Japan
JF - Journal of Otolaryngology of Japan
IS - 1
ER -